The present disclosure provides methods for identifying agents that are candidate agents for treating atopic dermatitis. The present disclosure provides methods for diagnosing atopic dermatitis. The present disclosure provides compositions and methods for treating atopic dermatitis.

A method of evaluating the health of skin, containing the steps of: preparing a lipid sample from a collected sample of a stratum corneum of a test subject; quantitatively determining respective contents of one kind of ceramide component A and one kind of ceramide component B included in the prepared lipid sample prepared from a collected sample of a stratum corneum of the test subject; calculating the content ratio of the quantitatively determined content of the ceramide component A to the quantitatively determined content of the ceramide component B; and evaluating the health of the skin of the test subject from the calculated content ratio;
wherein the ceramide component A is selected from the group consisting of a non-hydroxyacyl-phytosphingosine ceramide, a non-hydroxyacyl-6-hydroxysphingosine ceramide component, an esterified -hydroxyacyl-6-hydroxysphingosine ceramide component and an esterified -hydroxyacyl-phytosphingosine ceramide component; and the ceramide component B is selected from the group consisting of a non-hydroxyacyl-sphingosine ceramide and an -hydroxyacyl-sphingosine ceramide component.

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, such as atopic dermatitis, and to the prevention and treatment of these allergic diseases.

The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is affected by atopic dermatitis. Such markers are particularly advantageous in that they allow the skin's response to atopic dermatitis to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of atopic dermatitis on a child's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.

Disclosed herein are methods of identifying and/or screening infants at risk of developing atopic dermatitis by determining the expression level of various cytokines and lipids using a skin tape stripping method.

Provided is an objective and convenient index for judging full recovery from atopic dermatitis and severity thereof. The present invention provides a diagnosis assisting method for determining a treatment policy for an atopic dermatitis subject under the treatment, said method comprising: measuring the expression value of SCCA-1 in skin horny cells of the subject; i) when the SCCA-1 expression value is not statistically significantly higher than the level of those who do not suffer from atopic dermatitis, then determining that the continuation of the treatment for the disease becomes unnecessary thanks to the treatment; and, in the case where the continuation of the treatment is determined as still necessary, ii) ranking the severity of atopic dermatitis of the subject using the SCCA-1 expression value as an index and determining an adequate treatment method for atopic dermatitis to be given to the subject depending on the rank.

The present disclosure provides methods for identifying agents that are candidate agents for treating atopic dermatitis. The present disclosure provides methods for diagnosing atopic dermatitis. The present disclosure provides compositions and methods for treating atopic dermatitis.

The present invention provides an antibody specific to a C-terminal domain of a human profilaggrin gene, wherein the C-terminal domain is a peptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, a method for detecting a filaggrin gene mutation using the antibody, and a kit for the detection.

The present disclosure provides diagnostic methods, that may be combined with medical treatment, using one or more plasma biomarkers that are useful for identifying a subject with Hidradenitis Suppurativa (HS), measuring disease severity of HS, and measuring clinical response in subjects with HS.

The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition that modulate skin barrier permeability.